Wir benötigen Ihre Einwilligung zur Verwendung der einzelnen Daten, damit Sie unter anderem Informationen zu Ihren Interessen einsehen können. Klicken Sie auf "OK", um Ihre Zustimmung zu erteilen.
Standard Guide for Risk Assessment and Risk Control as it Impacts the Design, Development, and Operation of PAT Processes for Pharmaceutical Manufacture
Automatische name übersetzung:
Standard-Leitfaden für Risikobewertung und das Risikocontrolling, wie es wirkt sich auf die Entwicklung, Konstruktion und Betrieb von PAT-Prozesse für Farmen
NORM herausgegeben am 15.5.2009
Bezeichnung normen: ASTM E2476-09
Anmerkung: UNGÜLTIG
Ausgabedatum normen: 15.5.2009
SKU: NS-45391
Zahl der Seiten: 10
Gewicht ca.: 30 g (0.07 Pfund)
Land: Amerikanische technische Norm
Kategorie: Technische Normen ASTM
Keywords:
critical quality attribute (CQA), manufacturing, Process Analytical Technology (PAT), process understanding, risk management, ICS Number Code 11.120.10 (Medicaments)
Significance and Use | ||||||
This guide is intended to provide guidance regarding the use of risk analysis in the development, day-to-day running, and continuous improvement of pharmaceutical processes incorporating Process Analytical Technology (PAT). Since PAT is defined as being “risk-based” (see FDA Guidance for Industry), it is important that a consistent approach to the use of risk methodologies is adopted, to ensure rapid transfer of process understanding within the development and manufacturing teams, and to the regulators where that is appropriate. 4.2 This guidance only covers those aspects of risk assessment related to “risk to product quality.” Other aspects (such as “risk to patient”) should be covered in the conventional manner. |
||||||
1. Scope | ||||||
1.1 This document provides guidance on the assessment of risks to product quality within and related to PAT processes in the pharmaceutical industry. It addresses those risks to product quality arising from, associated with, identified by, or modified by the implementation of PAT in pharmaceutical development and manufacturing for primary, secondary, and biotech sectors of the industry. It does not replace those assessments of risk currently undertaken by pharmaceutical companies, but is, rather, an additional component focused specifically upon the evaluation and design of PAT processes. See Practice E 2474, Guide E 2500, and ICH Q8. 1.2 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use. Note that safety in this context refers to operational and operator safety, not to patient safety. |
||||||
2. Referenced Documents | ||||||
|
Historisch
15.12.2010
Historisch
1.8.2010
Historisch
1.6.2011
Historisch
1.8.2013
Historisch
1.2.2008
Historisch
15.3.2011
Bereitstellung von aktuellen Informationen über legislative Vorschriften in der Sammlung der Gesetze bis zum Jahr 1945.
Aktualisierung 2x pro Monat!
Brauchen Sie mehr Informationen? Sehen Sie sich diese Seite an.
Letzte Aktualisierung: 2024-12-22 (Zahl der Positionen: 2 217 000)
© Copyright 2024 NORMSERVIS s.r.o.